Beyond market averages, investors seeking exceptional growth focus on the art of stock selection. The right picks can significantly contribute to the expansion of your wealth.
The closing price of LENZ Therapeutics Inc (NASDAQ: LENZ) was $22.97 for the day, up 0.04% from the previous closing price of $22.96. In other words, the price has increased by $0.04 from its previous closing price. On the day, 1.7 million shares were traded. LENZ stock price reached its highest trading level at $23.93 during the session, while it also had its lowest trading level at $22.0101.
Ratios:
Our analysis of LENZ’s different ratios will help us gain a deeper understanding of the company. For the most recent quarter (mrq), Quick Ratio is recorded 12.63 and its Current Ratio is at 12.69. In the meantime, Its Debt-to-Equity ratio is 0.00 whereas as Long-Term Debt/Eq ratio is at 0.00.
On March 18, 2025, TD Cowen started tracking the stock assigning a Buy rating and target price of $60.
On September 27, 2024, Raymond James started tracking the stock assigning a Outperform rating and target price of $37.Raymond James initiated its Outperform rating on September 27, 2024, with a $37 target price.
Insider Transactions:
Also, insider trades can serve as a great indicator of what management thinks about the future direction of a stock’s price. A recent insider transaction in this stock occurred on Nov 07 ’25 when Chevallard Daniel R. bought 2,198 shares for $22.76 per share. The transaction valued at 50,017 led to the insider holds 5,386 shares of the business.
Versant Venture Capital VI, L. sold 132,944 shares of LENZ for $6,117,323 on Sep 30 ’25. The 10% Owner now owns 1,050,599 shares after completing the transaction at $46.01 per share. On Sep 30 ’25, another insider, Versant Venture Capital VI, L., who serves as the 10% Owner of the company, sold 92,030 shares for $46.01 each. As a result, the insider received 4,234,695 and left with 764,127 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, LENZ now has a Market Capitalization of 718730560 and an Enterprise Value of 517512576. For the stock, the TTM Price-to-Sale (P/S) ratio is 41.07 while its Price-to-Book (P/B) ratio in mrq is 3.39. Its current Enterprise Value per Revenue stands at 29.572 whereas that against EBITDA is -7.645.
Stock Price History:
The Beta on a monthly basis for LENZ is 0.59, which has changed by -0.3574825 over the last 52 weeks, in comparison to a change of 0.12121439 over the same period for the S&P500. Over the past 52 weeks, LENZ has reached a high of $50.40, while it has fallen to a 52-week low of $16.53. The 50-Day Moving Average of the stock is -40.16%, while the 200-Day Moving Average is calculated to be -25.70%.
Shares Statistics:
LENZ traded an average of 877.97K shares per day over the past three months and 1473020 shares per day over the past ten days. A total of 28.59M shares are outstanding, with a floating share count of 26.77M. Insiders hold about 14.45% of the company’s shares, while institutions hold 94.18% stake in the company. Shares short for LENZ as of 1760486400 were 5656845 with a Short Ratio of 6.44, compared to 1757894400 on 5020705. Therefore, it implies a Short% of Shares Outstanding of 5656845 and a Short% of Float of 32.98.
Earnings Estimates
The market rating of LENZ Therapeutics Inc (LENZ) is currently shaped by the ongoing analysis conducted by 5.0 analysts closely monitoring its performance.The consensus estimate for the next quarter is -$0.78, with high estimates of -$0.7 and low estimates of -$0.86.
Analysts are recommending an EPS of between -$2.45 and -$2.74 for the fiscal current year, implying an average EPS of -$2.62. EPS for the following year is -$2.63, with 7.0 analysts recommending between -$1.75 and -$3.65.
Revenue Estimates
For the next quarter, 3 analysts are estimating revenue of $3.2M. There is a high estimate of $4.1M for the next quarter, whereas the lowest estimate is $2.3M.
Based on 6 analysts’ estimates, the company’s revenue will be $54.11M in the next fiscal year. The high estimate is $60.59M and the low estimate is $44.6M.
